My Portfolio
+
LINK YOUR PORTFOLIO

BridgeBio Pharma Inc BBIO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
65.48UNCH (UNCH)
Volume
292,938
Close
65.48quote price arrow up+1.60 (+2.50%)
Volume
2,342,764
52 week range
35.15 - 84.94
Loading...
  • Open63.43
  • Day High65.85
  • Day Low62.71
  • Prev Close63.88
  • 52 Week High84.94
  • 52 Week High Date02/12/26
  • 52 Week Low35.15
  • 52 Week Low Date06/03/25

Key Stats

  • Market Cap12.825B
  • Shares Out195.86M
  • 10 Day Average Volume3.26M
  • Dividend-
  • Dividend Yield-
  • Beta0.98

KEY STATS

  • Open63.43
  • Day High65.85
  • Day Low62.71
  • Prev Close63.88
  • 52 Week High84.94
  • 52 Week High Date02/12/26
  • 52 Week Low35.15
  • 52 Week Low Date06/03/25
  • Market Cap12.825B
  • Shares Out195.86M
  • 10 Day Average Volume3.26M
  • Dividend-
  • Dividend Yield-
  • Beta0.98

RATIOS/PROFITABILITY

  • EPS (TTM)-3.75
  • P/E (TTM)-17.48
  • Fwd P/E (NTM)-41.03
  • EBITDA (TTM)-498.882M
  • ROE (TTM)-192.44%
  • Revenue (TTM)579.958M
  • Gross Margin (TTM)95.13%
  • Net Margin (TTM)-125.85%
  • Debt To Equity (MRQ)-146.80%

EVENTS

  • Earnings Date08/03/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for...
Neil Kumar Ph.D.
Chief Executive Officer, Director
Thomas Trimarchi Ph.D.
President, Chief Financial Officer
Address
3160 Porter Dr., Suite 250
Palo Alto, CA
94304
United States
https://bridgebio.com/